CME Information
Overview
Provider Statement
This continuing medical education activity is provided by 
Support Statement
This activity is supported by an educational grant from Daiichi Sankyo, Inc.
Target Audience
The intended audience for this activity is oncologists and other health care professionals involved in the management of patients with cancer.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Summarize the latest clinical data regarding the safety and efficacy of B7-H3–targeted antibody-drug conjugates and other therapeutic modalities.
- Outline distinctions between emerging B7-H3–targeted agents, including mechanisms and preliminary clinical outcomes.
- Describe how B7-H3–targeted agents might play a role in existing treatment paradigms.
Activity Chair
Melissa L. Johnson, MD
Program Director, Lung Cancer Research
Sarah Cannon Research Institute
Nashville, TN
Faculty
Charu Aggarwal, MD, MPH
Leslye M. Heisler Associate Professor of Medicine
Associate Director, Penn Center for Precision Medicine
Associate Director, Penn Center for Cancer Care Innovation (PC3I)
Physician Leader, Airways Malignancies Clinical Research
University of Pennsylvania
Philadelphia, PA
Robert L. Ferris, MD, PhD
Director, UPMC Hillman Cancer Center
Hillman Professor of Oncology
Associate Vice Chancellor for Cancer Research
Professor of Otolaryngology, of Immunology, and of Radiation Oncology
University of Pittsburgh
Philadelphia, PA
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, September 30, 2022, to September 29, 2023.
How to Participate in This Activity and Obtain CME Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of the 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Disclosures
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Activity Chair and Faculty report the following relevant financial relationship(s)
Charu Aggarwal, MD, MPH
Consultant: AstraZeneca, BeiGene, Blueprint Genetics, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eisai, Genentech, Janssen, Lilly, Merck, Pfizer, Regeneron/Sanofi, Shionogi, Turning Point
Independent Research Contractor (paid to institution): AstraZeneca/Medlmmune, Genentech/Roche, Incyte, Macrogenics, Merck
Robert L. Ferris, MD, PhD
Advisor: Achilles Therapeutics, Bristol Myers Squibb, Coherus BioSciences, Hookipa Biotech GmbH, Instil Bio, Lifescience Dynamics, MacroGenics, MeiraGTx, Merck, Numab, OncoCyte, Pfizer, PPD, Rakuten Medical, Seagen, SIRPant, Vir
Consultant: Adagene, Aduro Biotech, Bicara, Brooklyn lmmunotherapeutics, Catenion, EMD Serono, Everest Clinical Research, Genocea, Kowa Research Institute, Mirati, Nanobiotix, Novartis, Novasenta, Roche, Sanofi, Zymeworks
Independent Research Contractor: AstraZeneca/MedImmune, Bristol Myers Squibb, Merck, Novasenta, Tesaro
Individual Stocks and Stock Options: Novasenta
Data Safety Monitoring Board: Mirror Biologics
Advisory Board: Achilles Therapeutics, Lifescience Dynamics, MacroGenics, MeiraGTx, Merck, Numab, Oncocyte, PPD, Pfizer, Rakuten Medical, SIRPant, lmmunotherapeutics, Seagen, Vir Biotechnology
Melissa L. Johnson, MD
Consultant (paid to institution): AbbVie, Amgen, Astellas, AstraZeneca, Axelia Oncology, Black Diamond, Calithera, Checkpoint Therapeutics, CytomX Therapeutics, Daiichi Sankyo, EcoR1, Editas, Eisai, EMD Serono, G1 Therapeutics, Genentech/Roche, Genmab, Genocea Biosciences, GSK, Gritstone, IDEAYA, iTeos, Janssen, Lilly, Merck, Mirati, Molecular Axiom, Novartis, Oncorus, Regeneron, Ribon, Sanofi, Turning Point, VBL Therapeutics
Independent Research Contractor (paid to institution): AbbVie, Acerta, Adaptimmune, Amgen, Apexigen, Arcus, Array, Artios, AstraZeneca, Atreca, BeiGene, BerGenBio, BioAtla, Black Diamond, Boehringer Ingelheim, Calithera, Carisma, Corvus Pharmaceuticals, Curis, CytomX, Daiichi Sankyo, Dracen, Dynavax, Lilly, Elicio, EMD Serono, EQRx, Erasca, Exelixis, Fate Therapeutics, Genentech/Roche, Genmab, Genocea Biosciences, GSK, Gritstone Oncology, Guardant Health, Harpoon, Helsinn, Hengrui Therapeutics, HUTCHMED, IDEAYA, IGM Biosciences, Immunocore, Impact, Incyte, Janssen, Kadmon, Kartos, Loxo, Lycera, MSK, Merck, Merus, Mirati, NeoImmuneTech, Neovia, Novartis, Numab, Nuvalent, OncoMed, Palleon, Pfizer, PMV Pharmaceuticals, Rain Therapeutics, RasCal Therapeutics, Regeneron, Relay, Revolution Medicines, Ribon, Rubius Therapeutics, Sanofi, Seven and Eight Biopharmaceuticals / Birdie Biopharmaceuticals, Shattuck Labs, Silicon Therapeutics, Syndax, Takeda, Tarveda, TCR2 Therapeutics, Tempest Therapeutics, Tizona, TMUNITY, Turning Point, University of Michigan, Vyriad, Y‐mAbs Therapeutics
Reviewer reports the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com